SciClone Pharmaceuticals (Holdings) Resultados de beneficios anteriores

Pasado controles de criterios 6/6

SciClone Pharmaceuticals (Holdings) ha aumentado sus beneficios a una tasa media anual de 11.2%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 5.9% anual. Los ingresos han ido creciendo a una tasa media de 14.8% al año. La rentabilidad financiera de SciClone Pharmaceuticals (Holdings) es de 34.4%, y sus márgenes netos son de 35.6%.

Información clave

11.2%

Tasa de crecimiento de los beneficios

7.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	5.6%
Tasa de crecimiento de los ingresos	14.8%
Rentabilidad financiera	34.4%
Margen neto	35.6%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero SciClone Pharmaceuticals (Holdings). Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SZSC:6600 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	3,156	1,122	970	171
30 Sep 23	3,017	1,038	889	159
30 Jun 23	2,878	953	808	147
31 Mar 23	2,814	904	781	135
31 Dec 22	2,750	855	753	124
30 Sep 22	2,706	844	738	134
30 Jun 22	2,662	833	724	145
31 Mar 22	2,590	878	726	140
31 Dec 21	2,518	923	729	134
30 Sep 21	2,259	837	742	114
30 Jun 21	2,089	779	753	85
31 Mar 21	2,004	766	703	80
31 Dec 20	1,919	754	653	75
30 Sep 20	2,001	817	615	77
31 Dec 19	1,708	615	579	88
31 Dec 18	1,409	535	533	77
31 Dec 17	1,213	20	728	83
30 Jun 17	1,166	294	586	96
31 Mar 17	1,146	258	587	111
31 Dec 16	1,112	213	591	105
30 Sep 16	1,060	246	544	88
30 Jun 16	1,072	257	550	72
31 Mar 16	1,034	183	515	82
31 Dec 15	1,021	191	509	80
30 Sep 15	991	130	488	129
30 Jun 15	913	102	458	124
31 Mar 15	879	186	442	88
31 Dec 14	836	156	426	90
30 Sep 14	774	133	429	29
30 Jun 14	790	140	467	28
31 Mar 14	770	68	499	57
31 Dec 13	769	66	510	49
30 Sep 13	780	78	541	35
30 Jun 13	816	-56	530	37

Ingresos de calidad: 6600 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (35.6%) de 6600 son superiores a los del año pasado (31.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 6600 han crecido un 11.2% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 6600 en el último año (31.2%) supera su media de 5 años (11.2% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 6600 en el último año (31.2%) superó al de la industria Pharmaceuticals 1.3%.

SciClone Pharmaceuticals (Holdings) Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: EPS: CN¥1.83 (vs CN¥1.27 in FY 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

Full year 2022 earnings released: EPS: CN¥1.27 (vs CN¥1.42 in FY 2021)

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

Recent updates

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings released: EPS: CN¥1.83 (vs CN¥1.27 in FY 2022)

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings released: EPS: CN¥1.27 (vs CN¥1.42 in FY 2021)

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta